| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051846624 |
| P356 | DOI | 10.1038/SJ.ONC.1203957 |
| P3181 | OpenCitations bibliographic resource ID | 1043558 |
| P698 | PubMed publication ID | 11114734 |
| P5875 | ResearchGate publication ID | 12212947 |
| P50 | author | Su-Fang Lin | Q72169957 |
| P2093 | author name string | Wu YM | |
| Robinson DR | |||
| P2860 | cites work | ESTablishing a human transcript map | Q72048152 |
| Mouse Ror2 receptor tyrosine kinase is required for the heart development and limb formation | Q73395719 | ||
| Insulin-like growth factor I receptor signaling--overlapping or redundant pathways? | Q73621905 | ||
| RTK mutations and human syndromes: when good receptors turn bad | Q74029167 | ||
| FLT3: receptor and ligand. Biology and potential clinical application | Q77163163 | ||
| The many faces of Src: multiple functions of a prototypical tyrosine kinase | Q77436410 | ||
| Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development | Q77808307 | ||
| The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 | Q107343694 | ||
| Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK | Q22009973 | ||
| Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene | Q24305125 | ||
| Basic local alignment search tool | Q25938991 | ||
| The Pfam protein families database. | Q27861012 | ||
| The protein kinases of budding yeast: six score and more | Q27930077 | ||
| Tec family of protein-tyrosine kinases: an overview of their structure and function | Q28143299 | ||
| Tec kinases: a family with multiple roles in immunity | Q28143522 | ||
| Protein tyrosine kinase structure and function | Q28145008 | ||
| Tyrosine kinase SYK: essential functions for immunoreceptor signalling | Q28145413 | ||
| Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias | Q28236745 | ||
| Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members | Q28250257 | ||
| The ephrins and Eph receptors in neural development | Q28266706 | ||
| The c-Fes family of protein-tyrosine kinases | Q28283854 | ||
| Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase | Q28286701 | ||
| Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system | Q28304840 | ||
| AATYK: a novel tyrosine kinase induced during growth arrest and apoptosis of myeloid cells | Q28590932 | ||
| Ryk is expressed in a differentiation-specific manner in epithelial tissues and is strongly induced in decidualizing uterine stroma | Q28594165 | ||
| EGF receptor | Q28646107 | ||
| The Syk family of protein tyrosine kinases in T-cell activation and development | Q28647330 | ||
| Vascular endothelial growth factor (VEGF) and its receptors | Q29615390 | ||
| Cellular functions regulated by Src family kinases | Q29616038 | ||
| Active and inactive protein kinases: structural basis for regulation | Q29616320 | ||
| Signaling--2000 and beyond | Q29617413 | ||
| Growth factor signaling by receptor tyrosine kinases | Q29618315 | ||
| Jaks and STATs: biological implications | Q29619657 | ||
| Domain interactions in protein tyrosine kinase Csk. | Q30175369 | ||
| A novel nonreceptor tyrosine kinase, Srm: cloning and targeted disruption | Q30194028 | ||
| NCBI's LocusLink and RefSeq | Q30825874 | ||
| Introducing RefSeq and LocusLink: curated human genome resources at the NCBI. | Q30833186 | ||
| Protein kinases and phosphatases in the Drosophila genome | Q30887459 | ||
| Signal perception and transduction: the role of protein kinases | Q33540927 | ||
| Epidermal growth factor receptors: critical mediators of multiple receptor pathways | Q33597368 | ||
| Discoidin domain receptors: structural relations and functional implications | Q33648751 | ||
| FAK and PYK2/CAKbeta in the nervous system: a link between neuronal activity, plasticity and survival? | Q33650545 | ||
| Janus kinases and their role in growth and disease | Q33664276 | ||
| Chemical approaches to the study of protein tyrosine kinases and their implications for mechanism and inhibitor design | Q33716117 | ||
| RET proto-oncogene in the development of human cancer | Q33718087 | ||
| Cell signaling by protein tyrosine phosphorylation | Q33724532 | ||
| Ephrins and their Eph receptors: multitalented directors of embryonic development | Q33744607 | ||
| Evolution of the vertebrate neurotrophin and Trk receptor gene families | Q33745309 | ||
| The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms | Q33777991 | ||
| The IGF-I receptor in cancer research | Q33783474 | ||
| The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis | Q33783517 | ||
| Src family tyrosine kinases and growth factor signaling | Q33810017 | ||
| Growth factor signaling pathways in vascular development | Q33814336 | ||
| New roles for Src kinases in control of cell survival and angiogenesis | Q33838903 | ||
| From Abl to actin: Abl tyrosine kinase and associated proteins in growth cone motility | Q33840680 | ||
| RAFTK/Pyk2-mediated cellular signalling | Q33855347 | ||
| Early events in M-CSF receptor signaling | Q33855769 | ||
| Signalling through the insulin receptor | Q33860499 | ||
| Tec family kinases in lymphocyte signaling and function | Q33898915 | ||
| The Jak-STAT pathway | Q33899139 | ||
| The RET receptor tyrosine kinase: activation, signalling and significance in neural development and disease | Q33919864 | ||
| The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. | Q33922881 | ||
| EGF receptor signalling: the importance of presentation | Q33932869 | ||
| Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis | Q33933866 | ||
| JAK-STAT signaling activated by Abl oncogenes | Q33941370 | ||
| Control of cell behaviour by signalling through Eph receptors and ephrins. | Q33941577 | ||
| The insulin receptor: from protein sequence to structure. | Q33985665 | ||
| Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer | Q33989023 | ||
| Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG. | Q34403860 | ||
| Vertebrate non-receptor protein-tyrosine kinase families | Q34425007 | ||
| Ctk: a protein-tyrosine kinase related to Csk that defines an enzyme family | Q35124455 | ||
| A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation | Q36821163 | ||
| The Mouse Genome Database (MGD): expanding genetic and genomic resources for the laboratory mouse. The Mouse Genome Database Group | Q39541591 | ||
| Structural and functional properties of the TRK family of neurotrophin receptors | Q40374660 | ||
| The Trk family of neurotrophin receptors | Q40590908 | ||
| Tyrosine kinase receptors in the control of epithelial growth and morphogenesis during development | Q40853801 | ||
| The Src and Csk families of tyrosine protein kinases in hemopoietic cells. | Q40921703 | ||
| The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function | Q40921713 | ||
| Abl tyrosine protein kinase | Q40921721 | ||
| Nuclear tyrosine kinases: from Abl to WEE1. | Q41099672 | ||
| Oncoprotein networks | Q41352439 | ||
| Signal transduction by the neurotrophin receptors | Q41382912 | ||
| The HGF receptor family: unconventional signal transducers for invasive cell growth | Q41458148 | ||
| New insights into the control of cell growth; the role of the AxI family | Q41523439 | ||
| Sequential roles of agrin, MuSK and rapsyn during neuromuscular junction formation | Q41541455 | ||
| Eph-related receptors and their ligands: mediators of contact dependent cell interactions | Q41594083 | ||
| Direct binding and activation of receptor tyrosine kinases by collagen | Q41681111 | ||
| A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division | Q41688982 | ||
| The Src/Csk regulatory circuit arose early in metazoan evolution. | Q41756921 | ||
| Autoregulatory mechanisms in protein-tyrosine kinases | Q41758716 | ||
| Paralogy and orthology of tyrosine kinases that can extend the life span of Caenorhabditis elegans | Q42624801 | ||
| MetaBlasts: tracing protein tyrosine phosphatase gene family roots from Man to Drosophila melanogaster and Caenorhabditis elegans genomes. | Q42631613 | ||
| Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms | Q42857007 | ||
| Gene structure and function of tyrosine kinases in the marine sponge Geodia cydonium: autapomorphic characters in Metazoa | Q47695455 | ||
| Integrin signalling and tyrosine phosphorylation: just the FAKs? | Q47721433 | ||
| Signaling by Eph receptors and their ephrin ligands | Q47754321 | ||
| The family of Caenorhabditis elegans tyrosine kinase receptors: similarities and differences with mammalian receptors | Q47909945 | ||
| Extensive gene duplication in the early evolution of animals before the parazoan-eumetazoan split demonstrated by G proteins and protein tyrosine kinases from sponge and hydra | Q47967462 | ||
| Role of focal adhesion proteins in signal transduction and oncogenesis | Q47988371 | ||
| The protein tyrosine kinases of the sea urchin Anthocidaris crassispina | Q48039297 | ||
| Sperm-egg binding protein or proto-oncogene? | Q48065655 | ||
| Guidelines for human gene nomenclature (1997). HUGO Nomenclature Committee | Q48772399 | ||
| Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. | Q52183100 | ||
| Mutations of theRET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease | Q57591326 | ||
| Neuronal and non-neuronal Trk neurotrophin receptor-like proteins in Eisenia foetida (Annelida Oligochaeta) | Q63283467 | ||
| P433 | issue | 49 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5548-5557 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | The protein tyrosine kinase family of the human genome | |
| P478 | volume | 19 |
| Q54277967 | 3D-QSAR study of tetrahydro-3H-imidazo[4,5-c]pyridine derivatives as VEGFR-2 kinase inhibitors using various charge schemes. |
| Q48058260 | 3D-modeling of carboxyl-terminal phosphorylation of plant αβ-tubulin and its role in kinesin-8/microtubule interaction. |
| Q93064606 | A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis |
| Q37502925 | A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice |
| Q49881127 | A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors |
| Q42643080 | A positive feedback loop between Gli1 and tyrosine kinase Hck amplifies shh signaling activities in medulloblastoma |
| Q24555053 | A receptor tyrosine kinase from choanoflagellates: molecular insights into early animal evolution |
| Q34754663 | A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis |
| Q35171274 | ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors |
| Q28289188 | ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation |
| Q38727237 | AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex |
| Q48125350 | Aberrations in sperm DNA methylation patterns of males suffering from reduced fecundity |
| Q33321374 | Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis |
| Q28512899 | Absence of Fer protein tyrosine kinase exacerbates endotoxin induced intestinal epithelial barrier dysfunction in vivo |
| Q38824661 | Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling |
| Q34463388 | Activation of RAS family members confers resistance to ROS1 targeting drugs. |
| Q34801318 | Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation |
| Q38934587 | Advances in mass spectrometry based strategies to study receptor tyrosine kinases. |
| Q90468740 | Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications |
| Q30368055 | Allosteric pathway identification through network analysis: from molecular dynamics simulations to interactive 2D and 3D graphs. |
| Q54606951 | Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. |
| Q33418958 | Analyses of domains and domain fusions in human proto-oncogenes |
| Q34064118 | Analysis of protein glycosylation and phosphorylation using liquid phase separation, protein microarray technology, and mass spectrometry |
| Q46759433 | Ancient divergence of animal protein tyrosine kinase genes demonstrated by a gene family tree including choanoflagellate genes |
| Q47095393 | Angiogenesis Inhibitors in NSCLC. |
| Q35749794 | Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases |
| Q61807743 | Anti-Inflammatory Role of TAM Family of Receptor Tyrosine Kinases Via Modulating Macrophage Function |
| Q37407102 | Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells |
| Q47137229 | Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells |
| Q93143659 | Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting |
| Q24296670 | Apoptosis-associated tyrosine kinase is a Cdk5 activator p35 binding protein |
| Q34608164 | Apoptosis-associated tyrosine kinase scaffolding of protein phosphatase 1 and SPAK reveals a novel pathway for Na-K-2C1 cotransporter regulation |
| Q30497156 | Application of computational approaches to study signalling networks of nuclear and Tyrosine kinase receptors |
| Q39911160 | Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis |
| Q36192716 | Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics |
| Q36435120 | Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions |
| Q36223356 | Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia |
| Q39256469 | Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma |
| Q35539956 | Azoospermia in mice with targeted disruption of the Brek/Lmtk2 (brain-enriched kinase/lemur tyrosine kinase 2) gene |
| Q37997079 | BMX and its role in inflammation, cardiovascular disease, and cancer. |
| Q35771147 | Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders |
| Q28204688 | Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck |
| Q33531517 | Bioinformatic search of plant microtubule-and cell cycle related serine-threonine protein kinases. |
| Q29248463 | Biological Chemistry and Functionality of Protein Sulfenic Acids and Related Thiol Modifications |
| Q37689788 | BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome |
| Q42363585 | Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma |
| Q48157762 | Catalytic Metallodrugs: Substrate-Selective Metal Catalysts as Therapeutics. |
| Q38548494 | Catalytic specificity of human protein tyrosine kinases revealed by Peptide substrate profiling |
| Q50231132 | Cerebral artery signal transduction mechanisms: developmental changes in dynamics and Ca2+ sensitivity |
| Q43261590 | Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial |
| Q24298470 | Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis |
| Q34441584 | Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak |
| Q46857005 | Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. |
| Q38634706 | Chemical synthesis of transmembrane peptide and its application for research on the transmembrane-juxtamembrane region of membrane protein |
| Q36669662 | Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors |
| Q28260664 | Chemogenomics: an emerging strategy for rapid target and drug discovery |
| Q26744393 | Choanoflagellate models - Monosiga brevicollis and Salpingoeca rosetta |
| Q26797245 | Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory Analysis |
| Q34557003 | Class III receptor tyrosine kinases: role in leukaemogenesis |
| Q36240739 | Clinical pharmacokinetics of imatinib |
| Q43841175 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles |
| Q36074307 | Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. |
| Q37372107 | Comparative analysis of gene transcripts for cell signaling receptors in bone marrow-derived hematopoietic stem/progenitor cell and mesenchymal stromal cell populations |
| Q37492625 | Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. |
| Q89621491 | Comprehensive Analysis of Copy Number Variations in Kidney Cancer by Single-Cell Exome Sequencing |
| Q39842135 | Comprehensive Expression Profiles of Genes for Protein Tyrosine Phosphatases in Immune Cells |
| Q30164519 | Conformation of full-length Bruton tyrosine kinase (Btk) from synchrotron X-ray solution scattering. |
| Q35620042 | Controlling Abl: auto-inhibition and co-inhibition? |
| Q39324501 | Covalent inhibition of protein tyrosine phosphatases |
| Q36405628 | Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology |
| Q35596686 | Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond |
| Q34675896 | Cross signaling, cell specificity, and physiology |
| Q43469976 | Cross-membrane signal transduction of receptor tyrosine kinases (RTKs): from systems biology to systems pharmacology |
| Q41133765 | Current approach in the treatment of hepatocellular carcinoma |
| Q34586272 | Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab |
| Q37790985 | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| Q26740067 | Current targeted therapies in the treatment of advanced colorectal cancer: a review |
| Q37860149 | Dancing with the dead: Eph receptors and their kinase-null partners |
| Q90592084 | Deep phosphoproteome analysis of Schistosoma mansoni leads development of a kinomic array that highlights sex-biased differences in adult worm protein phosphorylation |
| Q40569549 | Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo |
| Q40277976 | Design, synthesis, in silico toxicity prediction, molecular docking, and evaluation of novel pyrazole derivatives as potential antiproliferative agents |
| Q35983152 | Designing and optimization of novel human LMTK3 inhibitors against breast cancer - a computational approach |
| Q36444609 | Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features |
| Q35155736 | Determinants of substrate recognition in nonreceptor tyrosine kinases |
| Q35168745 | Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication |
| Q38694303 | Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. |
| Q37294055 | Dimeric approaches to anti-cancer chemotherapeutics |
| Q44468454 | Discoidin domain receptors guide axons along longitudinal tracts in C. elegans |
| Q90223411 | Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine |
| Q33636171 | Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability |
| Q34975439 | Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays |
| Q48238438 | Discovery of wt RET and V804M RET Inhibitors: From Hit to Lead |
| Q45960008 | Discriminating of ATP competitive Src kinase inhibitors and decoys using self-organizing map and support vector machine. |
| Q28594723 | Distinct roles of the Src family kinases, SRC-1 and KIN-22, that are negatively regulated by CSK-1 in C. elegans |
| Q58052944 | Diversification of Lrk/Tak kinase gene clusters is associated with subfunctionalization and cultivar-specific transcript accumulation in barley |
| Q38200653 | Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery |
| Q33860674 | Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells |
| Q33847457 | Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer |
| Q38386866 | Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma |
| Q38623361 | Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. |
| Q38653045 | Emerging targeted therapies in non-small cell lung cancer |
| Q36302855 | Emerging targeted treatments for malignant glioma |
| Q34277301 | Enhanced endotoxin sensitivity in fps/fes-null mice with minimal defects in hematopoietic homeostasis. |
| Q24294625 | Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactome |
| Q37031466 | Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. |
| Q38604854 | Entrectinib: a potent new TRK, ROS1, and ALK inhibitor |
| Q47656937 | Epidermal Growth Factor Receptor Signaling Disruption by Endocrine and Metabolic Disrupting Chemicals. |
| Q39356240 | Epigenetic regulation of RTK signaling |
| Q56487095 | Evolution of the VEGF-Regulated Vascular Network from a Neural Guidance System |
| Q28972291 | Evolving Therapies and FAK Inhibitors for the Treatment of Cancer |
| Q41822673 | Ex vivo multiplex profiling of protein tyrosine kinase activities in early stages of human lung adenocarcinoma. |
| Q30445468 | Expression and function of a family of transmembrane kinases from the protozoan parasite Entamoeba histolytica |
| Q44544392 | Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium |
| Q34394070 | Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression |
| Q38053052 | Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases |
| Q37995562 | FMS Kinase Inhibitors: Current Status and Future Prospects. |
| Q54550204 | Fibroblast polarization is a matrix-rigidity-dependent process controlled by focal adhesion mechanosensing. |
| Q52726149 | Fine-tuning of substrate preferences of the Src-family kinase Lck revealed through a high-throughput specificity screen. |
| Q36939898 | Flying under the radar: the new wave of BCR-ABL inhibitors |
| Q27664940 | Functional Importance of Tyrosine 294 and the Catalytic Selectivity for the Bis-Fe(IV) State of MauG Revealed by Replacement of This Axial Heme Ligand with Histidine, |
| Q36512142 | Fusion tyrosine kinases: a result and cause of genomic instability |
| Q33514834 | Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma |
| Q90469547 | Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis |
| Q34810958 | Genetic profiling of colon cancer |
| Q34181602 | Genetic susceptibility on CagA-interacting molecules and gene-environment interaction with phytoestrogens: a putative risk factor for gastric cancer |
| Q54120207 | Genome-Wide Identification and Characterization of Tyrosine Kinases in the Silkworm, Bombyx mori. |
| Q42489683 | Genome-wide screening reveals the emergence and divergence of RTK homologues in basal Metazoan Hydra magnipapillata |
| Q44255021 | Genomic compartmentalization of gene families encoding core components of metazoan signaling systems |
| Q37738460 | Genomic instability: The cause and effect of BCR/ABL tyrosine kinase |
| Q33239001 | Graph theoretical insights into evolution of multidomain proteins |
| Q38559704 | Growth factors: the journey continues |
| Q24803647 | Human members of the eukaryotic protein kinase family |
| Q46651920 | Human umbilical tissue-derived cells rescue retinal pigment epithelium dysfunction in retinal degeneration |
| Q28550424 | Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization |
| Q38618837 | Identification and characterization of tyrosine kinases in anole lizard indicate the conserved tyrosine kinase repertoire in vertebrates. |
| Q47322561 | Identification of Biological and Pharmaceutical Mast Cell- and Basophil-Related Targets. |
| Q54979886 | Identification of curcumin derivatives as human LMTK3 inhibitors for breast cancer: a docking, dynamics, and MM/PBSA approach. |
| Q28207891 | Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases |
| Q28754824 | Identification of receptor-tyrosine-kinase-signaling target genes reveals receptor-specific activities and pathway branchpoints during Drosophila development |
| Q44979228 | Identification of tyrosine kinases expressed in the male mouse gubernaculum during development |
| Q31133907 | Identifying Significant Features in Cancer Methylation Data Using Gene Pathway Segmentation |
| Q98464891 | Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells |
| Q52661192 | In Silico Design and in Vitro Characterization of Universal Tyrosine Kinase Peptide Substrates. |
| Q39821325 | In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation |
| Q25256692 | Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line |
| Q46818387 | Indeno[1,2-d]pyrido[1,2-a]pyrimidines: a new class of receptor tyrosine kinase inhibitors |
| Q38270107 | Inhibiting Eph kinase activity may not be "Eph"ective for cancer treatment. |
| Q36764876 | Inhibiting kinases in malignant gliomas |
| Q33227206 | Inhibition of EGFR signaling: all mutations are not created equal |
| Q47253710 | Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480. |
| Q37316174 | Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program |
| Q41247922 | Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells |
| Q35777616 | Interaction of purinergic receptors with GPCRs, ion channels, tyrosine kinase and steroid hormone receptors orchestrates cell function |
| Q28576058 | Interactions between Src family protein tyrosine kinases and PSD-95 |
| Q34749542 | Interleukin-1 receptor-associated kinase-2 (IRAK2) is a critical mediator of endoplasmic reticulum (ER) stress signaling |
| Q37728343 | Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. |
| Q50520130 | Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. |
| Q39805970 | Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance |
| Q37676769 | Lemur tyrosine kinase-3 is a significant prognostic marker for patients with colorectal cancer |
| Q37101002 | Linear combinations of docking affinities explain quantitative differences in RTK signaling |
| Q49404537 | Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report |
| Q24548241 | Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases |
| Q38167461 | MET receptor tyrosine kinase as an autism genetic risk factor |
| Q38089834 | Malignant glioma drug discovery - targeting protein kinases |
| Q49888000 | Mechanisms of receptor tyrosine kinase activation in cancer |
| Q30982409 | Microarray Analysis of the Major Depressive Disorder mRNA Profile Data |
| Q28070028 | Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy |
| Q37942072 | Molecular aspects of renal cell carcinoma: a review |
| Q40071000 | Molecular docking guided 3D-QSAR CoMFA analysis of N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase |
| Q40188101 | Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases |
| Q33828409 | Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy |
| Q34347504 | Molecular pathways: ROS1 fusion proteins in cancer |
| Q37003665 | Molecular targeted therapies in hepatocellular carcinoma |
| Q45876740 | Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. |
| Q36316869 | Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model |
| Q45907873 | Mutated ephrin receptor genes in non-small cell lung carcinoma and their occurrence with driver mutations-targeted resequencing study on formalin-fixed, paraffin-embedded tumor material of 81 patients. |
| Q54373177 | Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). |
| Q38357132 | Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies. |
| Q36156434 | N-acetylglucosaminyl 1-phosphate transferase: an excellent target for developing new generation breast cancer therapeutic |
| Q44646845 | Natural history and functional divergence of protein tyrosine kinases |
| Q49787562 | Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab. |
| Q27319837 | Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts |
| Q40590626 | Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation. |
| Q52582448 | Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. |
| Q36720089 | Novel tyrosine kinase signaling pathways: implications in vascular remodeling |
| Q37635295 | Nuclear protein kinases: still enigmatic components in plant cell signalling. |
| Q28189493 | Oncogenic kinase signalling |
| Q44287458 | Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies |
| Q57194341 | Overexpression of NPM–ALK induces different types of malignant lymphomas in IL-9 transgenic mice |
| Q37810947 | PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms |
| Q27853138 | PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations |
| Q37801868 | Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature |
| Q37389526 | Pathogenesis of lung cancer signalling pathways: roadmap for therapies |
| Q24298798 | Peptide microarray analysis of substrate specificity of the transmembrane Ser/Thr kinase KPI-2 reveals reactivity with cystic fibrosis transmembrane conductance regulator and phosphorylase |
| Q28080730 | Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond |
| Q42514701 | Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation |
| Q26825153 | Pharmacology and rationale for imatinib in the treatment of scleroderma |
| Q33963732 | Pharmacology of imatinib (STI571). |
| Q51118716 | Phosphoproteomics analysis identifies novel candidate substrates of the non-receptor tyrosine kinase, SRMS |
| Q30504709 | Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. |
| Q24293090 | Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual hydroxyamino acid specificity in a tyrosine kinase |
| Q36427519 | Phosphotyrosine recognition domains: the typical, the atypical and the versatile |
| Q46371577 | Photo-induced cytotoxicity and anti-metastatic activity of ruthenium(ii)-polypyridyl complexes functionalized with tyrosine or tryptophan |
| Q54378597 | Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer. |
| Q34171209 | Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus |
| Q50938980 | Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis. |
| Q54504171 | Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. |
| Q55066840 | Protein phosphorylation profiling identifies potential mechanisms for direct immunotoxicity. |
| Q28208294 | Proteolytic activation of ETK/Bmx tyrosine kinase by caspases |
| Q35729278 | Proteomics for nasal secretion analysis |
| Q40541990 | Purification and identification of protein-tyrosine kinase-binding proteins using synthetic phosphopeptides as affinity reagents |
| Q36378036 | Pyrimidine and purine analogues, effects on cell cycle regulation and the role of cell cycle inhibitors to enhance their cytotoxicity |
| Q35859573 | Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays |
| Q38803278 | Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity |
| Q37481329 | RNA interference as an anticancer therapy: a patent perspective |
| Q64941091 | RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin. |
| Q37777990 | ROS receptor tyrosine kinase: a new potential target for anticancer drugs |
| Q38002468 | ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway |
| Q38852070 | ROS1 fusions in cancer: a review |
| Q39102554 | ROS1 gene rearrangement and copy number gain in non-small cell lung cancer |
| Q37317847 | ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas |
| Q89967335 | Rational Drug Design of Axl Tyrosine Kinase Type I Inhibitors as Promising Candidates Against Cancer |
| Q38640765 | Recent Advances in Targeting ROS1 in Lung Cancer |
| Q52654047 | Receptor Tyrosine Kinase Ubiquitination and De-Ubiquitination in Signal Transduction and Receptor Trafficking. |
| Q58607138 | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| Q30315828 | Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease |
| Q38033672 | Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy |
| Q36065321 | Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin |
| Q37841746 | Receptor tyrosine kinases and their activation in melanoma. |
| Q35558528 | Receptor tyrosine kinases in normal and malignant haematopoiesis |
| Q28082793 | Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers |
| Q36738608 | Receptor tyrosine kinases: mechanisms of activation and signaling |
| Q41819306 | Receptor tyrosine kinases: molecular switches regulating CNS axon regeneration |
| Q30157090 | Reengineering the signaling properties of a Src family kinase |
| Q33944599 | Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer |
| Q47371096 | Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases. |
| Q35006333 | Regulation of ack-family nonreceptor tyrosine kinases |
| Q34271347 | Regulation of phagocytosis by TAM receptors and their ligands |
| Q24301621 | Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition |
| Q41693807 | Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer. |
| Q39802930 | Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer |
| Q34674715 | Retracted: Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells |
| Q38261470 | Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells |
| Q37183670 | Reversing multidrug resistance by tyrosine kinase inhibitors |
| Q42637698 | Role of ABC transporters in cancer chemotherapy. |
| Q90284727 | Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia |
| Q38328408 | Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells |
| Q33883849 | Role of receptor tyrosine kinases and their ligands in glioblastoma |
| Q28242840 | Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy |
| Q46132798 | Role of tyrosine kinases in tumor progression of the head and neck |
| Q37520844 | Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases |
| Q38841650 | Screening of multi-targeted natural compounds for receptor tyrosine kinases inhibitors and biological evaluation on cancer cell lines, in silico and in vitro. |
| Q35622986 | Selective targeting of antibody conjugated multifunctional nanoclusters (nanoroses) to epidermal growth factor receptors in cancer cells |
| Q33334075 | Sequence similarity network reveals common ancestry of multidomain proteins |
| Q45732972 | Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis |
| Q33598601 | Serum-dependent selective expression of EhTMKB1-9, a member of Entamoeba histolytica B1 family of transmembrane kinases |
| Q37401172 | Sex-specific aspects of tumor therapy |
| Q28211506 | Signaling initiated by overexpression of the fibroblast growth factor receptor-1 investigated by mass spectrometry |
| Q34797452 | Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden. |
| Q37790248 | Sorafenib in hepatocellular carcinoma |
| Q60326103 | Spinal 5-HT7 receptor activation induces long-lasting phrenic motor facilitation |
| Q42665233 | Sponge homologs of vertebrate protein tyrosine kinases and frequent domain shufflings in the early evolution of animals before the parazoan-eumetazoan split |
| Q42066556 | Stretch-induced mitogen-activated protein kinase activation in lung fibroblasts is independent of receptor tyrosine kinases |
| Q34012560 | Structural and evolutionary relationships among protein tyrosine phosphatase domains |
| Q53659660 | Surrogate endpoints in cancer drug development. |
| Q54344110 | Synthesis and biological evaluation of new pyrimidine-4-yl-ethanol derivatives as ROS1 kinase inhibitors. |
| Q36121958 | Systematic analysis of phosphotyrosine antibodies recognizing single phosphorylated EPIYA-motifs in CagA of East Asian-type Helicobacter pylori strains |
| Q35163573 | Systematic analysis of phosphotyrosine antibodies recognizing single phosphorylated EPIYA-motifs in CagA of Western-type Helicobacter pylori strains |
| Q33770643 | Systematic deletion analysis of fission yeast protein kinases. |
| Q34794927 | TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer |
| Q93078108 | TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling |
| Q50999469 | TRPC Channels and Programmed Cell Death. |
| Q37725990 | Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins |
| Q90706409 | Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment |
| Q104289124 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer |
| Q92128519 | Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How? |
| Q26767351 | Targeting hypoxic response for cancer therapy |
| Q42769520 | Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine? |
| Q36280842 | Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. |
| Q34078275 | Targeting lymphatic vessel functions through tyrosine kinases |
| Q27013050 | Targeting receptor tyrosine kinases in gastric cancer |
| Q33620537 | Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond |
| Q49887906 | Targeting tumour microenvironment by tyrosine kinase inhibitor. |
| Q89910913 | The Emerging Role of Rab5 in Membrane Receptor Trafficking and Signaling Pathways |
| Q41591726 | The Escherichia coli effector EspJ blocks Src kinase activity via amidation and ADP ribosylation |
| Q53541067 | The Fps/Fes kinase regulates leucocyte recruitment and extravasation during inflammation. |
| Q94059147 | The Journey of Protein S from an Anticoagulant to a Signaling Molecule |
| Q36032222 | The Kinome of Pacific Oyster Crassostrea gigas, Its Expression during Development and in Response to Environmental Factors. |
| Q42477783 | The Meckel-Gruber syndrome protein TMEM67 controls basal body positioning and epithelial branching morphogenesis in mice via the non-canonical Wnt pathway |
| Q37602303 | The epidermal growth factor system of ligands and receptors in cancer |
| Q30157512 | The evolutionarily conserved arrangement of domains in SRC family kinases is important for substrate recognition |
| Q37098747 | The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties |
| Q28264717 | The intranuclear localization and function of YT521-B is regulated by tyrosine phosphorylation |
| Q41206091 | The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids |
| Q54616415 | The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. |
| Q38104686 | The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. |
| Q24802089 | The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules |
| Q24803062 | The repertoire of protein kinases encoded in the draft version of the human genome: atypical variations and uncommon domain combinations |
| Q38940140 | The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma |
| Q27007359 | The role of Eph receptors in lens function and disease |
| Q89634997 | The role of RICTOR amplification in targeted therapy and drug resistance |
| Q52669235 | The role of TAM family receptors and ligands in the nervous system: From development to pathobiology. |
| Q42777814 | The role of Tec kinase signaling pathways in the development of Mallory Denk Bodies in balloon cells in alcoholic hepatitis |
| Q39077751 | The secret life of kinases: functions beyond catalysis |
| Q39401758 | The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer |
| Q24297359 | The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1 |
| Q30636360 | The venus kinase receptor (VKR) family: structure and evolution |
| Q64265577 | Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft |
| Q51818965 | Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. |
| Q34661707 | Tissue repair: The hidden drama |
| Q33874421 | Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer |
| Q37944145 | Transglutaminases and receptor tyrosine kinases. |
| Q37704902 | Transmembrane helix-helix interactions involved in ErbB receptor signaling. |
| Q38208280 | Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy |
| Q47329331 | Tunicamycin-Induced ER Stress in Breast Cancer Cells Neither Expresses GRP78 on the Surface Nor Secretes it into the Media. |
| Q37565593 | Type II cGMP-dependent protein kinase inhibits activation of key members of the RTK family in gastric cancer cells |
| Q85037235 | Tyrosine kinase expression profile in clear cell renal cell carcinoma |
| Q28674280 | Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis |
| Q36977823 | Tyrosine kinase inhibitors in pediatric malignancies |
| Q34983846 | Tyrosine kinase inhibitors: Multi-targeted or single-targeted? |
| Q27692524 | Tyrosine kinase signaling and the emergence of multicellularity |
| Q34166503 | Tyrosine kinases in inflammatory dermatologic disease |
| Q33755097 | Tyrosine phosphorylation enrichment and subsequent analysis by MALDI-TOF/TOF MS/MS and LC-ESI-IT-MS/MS. |
| Q36646778 | Tyrosine-kinase expression profiles in human gastric cancer cell lines and their modulations with retinoic acids |
| Q35309992 | Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin |
| Q79903719 | Upregulation of discoidin domain receptor 2 in nasopharyngeal carcinoma |
| Q36230812 | Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma |
| Q45261205 | Using Illumina next generation sequencing technologies to sequence multigene families in de novo species |
| Q26823601 | Venus kinase receptors: prospects in signaling and biological functions of these invertebrate kinases |
| Q42575520 | Whole Genome Duplications Shaped the Receptor Tyrosine Kinase Repertoire of Jawed Vertebrates |
| Q81890266 | [Cellular mechanisms of tumor response: clinical demands] |
| Q37403951 | c-Abl and insulin receptor signalling |
| Q50985108 | c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences. |
| Q39722178 | erbB receptor expression patterns in human bladder cancer |
| Q34353437 | β-catenin contributes to lung tumor development induced by EGFR mutations |
Search more.